Skip to main content
CTOS 2023 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Valerae Lewis, MD

Chair
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Valerae O. Lewis, M.D.
Professor, Orthopaedic Oncology, Division of Surgery
Chair, Department of Orthopaedic Oncology, Division of Surgery
Dr. John Murray Professor in Orthopaedic Oncology
The University of Texas M. D. Anderson Cancer Center

Dr. Lewis, the John Murray Professor of Orthopaedic Oncology, attended Yale University and matriculated at Harvard Medical School, graduating with honors. She completed her Orthopaedic training at the Harvard Combined Orthopaedic Residency Program in Boston, MA and her fellowship in Musculoskeletal Oncology at the University of Chicago. The first African American woman to be awarded the MD Anderson Faculty Achievement Award in Patient Care she is now the Chair of the Department of Orthopaedic Surgery at MD Anderson.

Dr. Lewis is very active nationally and internationally within Orthopaedics and Musculoskeletal Oncology. She is a strong advocate of education, and as such, served as the Chair of the Musculoskeletal Tumor Society (MSTS) Education Committee, Chair of the American Academy of Orthopaedic Surgery (AAOS) Instructional Course Lecture Tumor Subcommittee, Chair of the Musculoskeletal Oncology Content Committee for the AAOS Council on Education and Chair of the International Society of Limb Salvage (ISOLS) Education Committee. A former board member of the American Orthopaedic Association, the Western Orthopaedic Association, the MSTS and ISOLS. She recently completed her tenure as the member-at-large on the Board of Directors of the AAOS

Dr. Lewis’ area of expertise is in the treatment of both children and adults with bone and soft tissue sarcomas. Her clinical research focuses on the outcome of patients after hemipelvectomy surgery and her lab investigates the gene functions tied to osteosarcoma and the development of treatments that might interrupt this process.

Disclosure information not submitted.

Presentation(s):